Suvemcitug not checked

Jiangsu Simcere Pharmaceutical Co., Ltd. · BD0801

FollowEvery change as it happens, and a Monday email
Next date
Phase 3 trial completes
Trials
1 active
3 in total
Targets
—
None known yet

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
How it’s given
“Suvemcitug injection at 1.5mg/kg, Trifluridine/tipiracil tablets at 35 mg/m²”In the company’s words, NCT07361003 on ClinicalTrials.gov
Tested for
Refractory Metastatic Colorectal Cancer
Main trialPhase 3
“The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants. The primary goal of Phase III Study is to evaluate the efficacy of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants. Researchers will compare Suvemcitug + trifluridine/tipiracil tablets with placebo (a look-alike substance that contains no drug)+ trifluridine/tipiracil tablets to see if Suvemcitug + trifluridine/tipiracil tablets works better in treating refractory metastatic colorectal…”In the company’s words, NCT07361003 on ClinicalTrials.gov
Other names
BD0801

Other drugs for Refractory Metastatic Colorectal Cancer

All 392 drugs for Refractory Metastatic Colorectal Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jan 2028 A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Phase 3Completed 8 Dec 2023 A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Phase 2Terminated 26 Jul 2023 A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Suvemcitug

Following is part of Solo: you see every change to Suvemcitug the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in